C1orf95 Inhibitors
Inhibitors of C1orf95 comprise a collection of chemical compounds that suppress the functional activity of the protein through various specific signaling pathways. Wortmannin and LY 294002, both PI3K inhibitors, reduce the activity of the PI3K/Akt signaling pathway, which, if associated with C1orf95, would result in its functional inhibition. Similarly, Rapamycin targets the mTOR pathway, another crucial regulator of cell proliferation and growth, and its inhibition could contribute to the suppression of C1orf95 if it plays a role in these cellular processes. Histone deacetylase inhibitor Trichostatin A could affect the expression and activity of C1orf95 by modifying chromatin structure and accessibility. The MAPK pathway inhibitors, such as SB 203580, PD 98059, SP600125, and U0126, each target different kinases within this signaling cascade, and their inhibition could lead to a decrease in C1orf95 activity if it is a downstream target.
The influence on C1orf95 extends to inhibitors of other signaling molecules and pathways. NF449, by selectively inhibiting the Gs-alpha subunit of G-proteins, might indirectly reduce C1orf95 activity if it isregulated by G-protein coupled receptor signaling. Brefeldin A's disruption of the Golgi apparatus may also indirectly lead to reduced activity of C1orf95 by interfering with its proper trafficking and processing. The role of PKC in regulating various cellular functions is targeted by Gö 6983, which could result in diminished activity of C1orf95 if PKC pathways are involved. Lastly, Sunitinib, a receptor tyrosine kinase inhibitor, by limiting the signaling that these kinases mediate, could also lead to a decrease in C1orf95 activity. Collectively, these inhibitors exert their effects on distinct signaling pathways and molecular processes that, when disrupted, are likely to contribute to the functional inhibition of C1orf95, regardless of the direct evidence linking these pathways to the protein.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. By suppressing the PI3K/Akt signaling pathway, it indirectly leads to reduced activation of downstream targets that may include C1orf95, thus diminishing its functional activity within the cell. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. Inhibition of the mTOR pathway can lead to the downregulation of several proteins involved in cell growth and proliferation. As C1orf95 is associated with such cellular processes, its activity can be indirectly diminished by rapamycin. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. It alters chromatin structure and accessibility, potentially affecting the expression levels of certain proteins including C1orf95, thereby reducing its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAPK. By inhibiting p38 MAPK, it impedes the signaling pathway that could indirectly decrease the functional activity of C1orf95 if it is a downstream effector. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is another PI3K inhibitor, similar to Wortmannin. It diminishes the PI3K/Akt pathway leading to decreased activity of proteins regulated by this pathway, possibly including C1orf95. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is an inhibitor of MEK, which works upstream of ERK in the MAPK pathway. By inhibiting this pathway, PD9 8059 can contribute to the reduced activity of C1orf95 if it is influenced by ERK signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK pathway. It can decrease the functional activity of proteins regulated by JNK signaling, which may encompass C1orf95. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that prevents the activation of MAPK/ERK, potentially leading to the inhibition of C1orf95 if it is a part of this signaling cascade. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $203.00 $469.00 $1509.00 | 1 | |
NF449 is a potent and selective inhibitor of Gs-alpha subunit of G-proteins. If C1orf95 is regulated by G-protein coupled receptor signaling, NF449 could indirectly diminish its activity. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts Golgi apparatus function and can impact the trafficking and function of proteins dependent on Golgi-mediated processing, potentially including C1orf95. | ||||||